Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report

Third-generation tyrosine kinase inhibitors are effective treatment of EGFR-mutated NSCLC. After an initial response, patients on this therapy ultimately develop resistance leading to disease progression. One of the resistance mechanisms is histological transformation to SCLC. There is no standard o...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Aditi Singh, MBBS, MPH, Arthi Sridhar, MBBS, Aastha Poddar, MBBS, Anastasios Dimou, MD, Kaushal Parikh, MBBS, Mohamed Shanshal, MD, Anna Schwecke, APRN, CNP, MS, Nicole Moffett, APRN, CNP, MSN, Manish R. Patel, DO, Aaron S. Mansfield, MD, Konstantinos Leventakos, MD, PhD
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2025-06-01
Edice:	JTO Clinical and Research Reports
Témata:	NSCLC SCLC EGFR Osimertinib Lurbinectedin Tranformed SCLC
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2666364325000232
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!